GlassScriptPhysician profile
Pawan Gundavaram
NPI 1174717300
$11,407.59
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $6,001 · 2021: $2,841 · 2022: $1,281 · 2023: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,301.64 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,633.94 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $1,138.18 | 2020-2021 | |
| Incyte Corporation | $582.13 | 2019-2022 | |
| Daiichi Sankyo INC. | $540.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $493.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $458.13 | 2019-2022 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Amgen INC. | $310.65 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $252.65 | 2019-2021 | |
| Seagen INC. | $230.72 | 2020-2022 | |
| Astellas Pharma US INC | $230.55 | 2019-2022 | |
| Pfizer INC. | $162.42 | 2019-2022 | |
| Celgene Corporation | $142.94 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $129.40 | 2020-2022 |
Show all 46 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pawan Gundavaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.